Company news

Hunan Warrant Pharmaceutical Co., Ltd. Class A (SSE:688799) news

Hunan Warrant Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement…

Hunan Warrant Pharmaceutical Co., Ltd. Class A (SSE:688799) news

Press releases & updates

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Shareholding Reduction Plan of Senior Executive

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Changes in the Equity Structure of the Controlling Shareholder

"Hunan Warrant Pharmaceutical Co., Ltd."Indicative Announcement on Change in Equity Interests of the Controlling Shareholder and Its Person Acting in Concert Reaching 1% Threshold

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Obtaining of the Approval Notice for Its API Marketing Application

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate

"Hunan Warrant Pharmaceutical Co., Ltd."Indicative Announcement on Shareholding Reduction Plan of Controlling Shareholder and Proposed Change of Shareholding Form by the Controlling Shareholder's Partner

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Increasing Cash Management Limit for Temporarily Idle Self-owned Funds

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Progress in Providing Guarantee for Wholly-owned Sub-subsidiary

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Supplementary Application

"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Change of Business Scope and Completion of Industrial and Commercial Change Registration by Controlling Shareholder

"Hunan Warrant Pharmaceutical Co., Ltd."Voluntary Disclosure Announcement on the Inclusion of the Company's Products in the National Essential Medicines List

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Adjusting Amount of Dividends per Share in 2025 Annual Profit Distribution Plan

Announcement on Voluntary Disclosure of Notice on Listing Application Approval for the Subsidiary's Active Pharmaceutical Ingredient

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Voluntary Disclosure of Subsidiary Passing GMP Compliance Inspection for Drugs

Announcement on Changing Venue of the 2025 Annual General Meeting

Announcement on Progress in Providing Guarantee for Wholly-owned Sub-subsidiary

Announcement on Changes in Equity Structure of Controlling Shareholders

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Announcement on Adjusting Grant Price and Amount in 2024 Restricted Stock Incentive Plan

Announcement on a Controlling Shareholder Adding a Person Acting in Concert and the Completion of Internal Transfer of Shares by Agreement Among Persons Acting in Concert

Indicative Announcement on a Controlling Shareholder Adding a Person Acting in Concert and the Internal Transfer of Shares by Agreement Among Persons Acting in Concert, Resulting in Change of Equity

Announcement on Voluntary Disclosure of Subsidiary Passing On-site Inspection by FDA

Announcement on Voluntary Disclosure of Subsidiary Passing ANVISA GMP Certification

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Voluntary Disclosure of Selection of Products for Continuation Procurement Under National Procurement Scheme After Agreement Expiry

Announcement on Voluntary Disclosure of Receipt by the Joint-stock Company of the Phase I Clinical Study Report for ZG-002 Tablets

Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License

Announcement on Voluntary Disclosure of Withdrawal of Drug Registration Application

Announcement on Resolutions of the 7th Extraordinary Meeting of the 4th Board of Directors

Announcement on Election of Employee Representative Directors for the 4th Board of Directors

Announcement on Changing Registered Capital, Canceling Board of Supervisors, Adjusting the Number Directors of the Board of Directors, Amending the "Articles of Association", Handling Industrial and Commercial Change Registration, and Formulating and Revising Some Governance Systems

Announcement on Resolutions of the 3rd Meeting of the 4th Board of Directors

Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement

Announcement on Progress in Co-investment with Related Parties in Capital Increase to Joint-stock Company and Related Party Transactions

Announcement on Shareholding Reduction Result of Shareholders, Directors and Their Persons Acting in Concert with Over 5% Shares

Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Hunan Jurisdiction and Semi-annual Performance Briefing

Announcement on Progress in Capital Increase of Holding Subsidiary to Introduce Strategic Investors and Related Party Transactions

Indicative Announcement on Changes in Equity Interests Reaching a Multiple of 5% by Shareholders and Directors Holding 5% or More of Shares and Their Persons Acting in Concert

Special Report on Semi-annual Deposit, Management and Actual Use of Raised Funds in 2025

Announcement on Shareholding Reduction Plan by Shareholders, Directors and Their Persons Acting in Concert with Over 5% Shares

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Announcement on Voluntary Disclosure of Drugs Passing Consistency Evaluation of Quality and Efficacy of Generic Drugs

Announcement on Correction of Announcement on Adjustment and Extension of Some Sub-projects of Investment Projects Financed by Raised Funds